24 October 2023
24 October 2023
Technology is having a significant impact in healthcare and its impact in the development of precision medicine is set to be huge.
The updated application includes supplemental information as requested by the FDA against the earlier application submitted in September.
The FDA’s decision on the approval of a higher dose of Dupixent in children is expected on 31 January 2024.
The Rybrevant regimen demonstrated a reduction in disease progression or mortality risk in patients.
Results from innovaTV 204 will serve as a confirmatory trial for US accelerated approval of Tivdak.
Subjects are currently being enrolled at five planned trial sites in Australia.
Protara’s Rare Paediatric Disease-designated drug is based on the immunopotentiator Picibanil, a therapy already approved in Japan.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
